Karyopharm Therapeutics Inc. Common Stock (KPTI)

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

228

Website

karyopharm.com/

Fundamentals

1-day range

$1.86$1.99

Market cap

$44.65M

P/E (trailing)

—

P/E (forward)

-0.66

EPS (trailing)

$-14.84

Dividend yield

—

Beta

0.97

Avg. volume

1.29M

Forecasts

4 analyst ratings

Karyopharm Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• KPTI

  Karyopharm Therapeutics Inc. Common Stock

  $1.88

  ▼ 3.09%
  Market cap $44.65MP/E —
  $1.79$10.99
• RADX

  Radiopharm Theranostics Limited American Depositary Shares

  $2.41

  ▲ 6.64%
  Market cap $44.71MP/E —
  $0.009$0.04
• TCRT

  Alaunos Therapeutics Inc. Common Stock

  $1.56

  ▼ 6.02%
  Market cap $46.52MP/E —
  $1.62$4.59
• RNXT

  RenovoRx Inc. Common Stock

  $1.68

  ▲ 13.18%
  Market cap $47.81MP/E —
  $0.7006$1.56
• IBO

  Impact BioMedical Inc. Common Stock

  $0.444

  ▲ 0.68%
  Market cap $48.61MP/E 0.52
  $0.37$0.83
• MREO

  Mereo BioPharma Group plc American Depositary Shares

  $0.2545

  ▼ 6.43%
  Market cap $48.95MP/E —
  $0.2$2.37
• HYPD

  Hyperion DeFi Inc. Common Stock

  $3.25

  ▼ 10.36%
  Market cap $40.32MP/E —
  $2.34$15

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Geron Corp.: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis
  SeekingAlpha · 8/18/2026
• Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/14/2026
• Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...
  Yahoo · 8/13/2026
• Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
  benzinga · 8/13/2026
• Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
  Yahoo · 8/13/2026
• Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
  Yahoo · 8/13/2026
• Karyopharm Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/13/2026
• Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
  Benzinga · 8/13/2026

• Poulton Stuart · July 28, 2026 · Sale

  189 @ $7.1
• Su Zhen · May 21, 2026 · Grant

  15.5K
• Oliger Christy J. · May 21, 2026 · Grant

  15.5K
• Chen Schor · May 21, 2026 · Grant

  15.5K
• Greene Barry E · May 21, 2026 · Grant

  15.5K
• Deepika Pakianathan · May 21, 2026 · Grant

  15.5K
• Garen G. Bohlin · May 21, 2026 · Grant

  15.5K
• Poulton Stuart · May 14, 2026 · Sale

  403 @ $9.5
• Rangwala Reshma · May 14, 2026 · Sale

  408 @ $9.5
• Cheng Sohanya Roshan · May 14, 2026 · Sale

  324 @ $9.5
• Abate Kristin · May 14, 2026 · Sale

  53 @ $9.5
• Paulson Richard A. · May 14, 2026 · Sale

  2.2K @ $9.5
• Mano Michael · May 14, 2026 · Sale

  266 @ $9.5
• Poulton Stuart · May 13, 2026 · Grant

  896
• Rangwala Reshma · May 13, 2026 · Grant

  947

Institutional Ownership

March 31, 2026

Total shares held

25.15M

Total value held

$129.49M

Institutional holders

80